The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein—；the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane； and—；the composition is administered to the eye of a subject； and—；the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 μg.
